148 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
7
Synthesis of Novel c(AmpRGD)-Sunitinib Dual Conjugates as Molecular Tools Targeting thea
University of Parma
4
Cyclic RGD peptidomimetics containing 4- and 5-amino-cyclopropane pipecolic acid (CPA) templates as dualaVß3 anda5ß1 integrin ligands.
University of Florence
5
Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.
Philipps-Universit£T Marburg
7
Pharmacophoric modifications lead to superpotentavß3 integrin ligands with suppresseda5ß1 activity.
Technische Universit£T M£Nchen
2
Synthesis and in vitro evaluation of a novel radioligand foravß3 integrin receptor imaging: [18F]FPPA-c(RGDfK).
University Hospital of Geneva
13
Modulation ofavß3- anda5ß1-integrin-mediated adhesion by dehydro-ß-amino acids containing peptidomimetics.
University of Bologna
8
Towards dual antithrombotic compounds - balancing thrombin inhibitory and fibrinogen GPIIb/IIIa binding inhibitory activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism.
University of Ljubljana
20
Biselectivity of isoDGR peptides for fibronectin binding integrin subtypesa5ß1 andavß6: conformational control through flanking amino acids.
Technische Universit£T M£Nchen
4
One step radiosynthesis of 6-[(18)F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester ([(18)F]F-Py-TFP): a new prosthetic group for efficient labeling of biomolecules with fluorine-18.
University of Troms£
2
Tetrazine-trans-cyclooctene ligation for the rapid construction of integrinavß3 targeted PET tracer based on a cyclic RGD peptide.
University of Delaware
6
Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging.
Washington University
8
Synthesis and evaluation of bivalent, peptidomimetic antagonists of theavß3 integrins.
The Methodist Hospital Research Institute
10
Inhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics.
University of Bologna
26
Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening.
Peking Union Medical College
8
Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents.
University of Southern California
2
Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior.
University of Naples Federico Ii
8
Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors.
Washington University
3
Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery.
University of Southern California
11
Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis.
Merck Research Laboratories
33
Non-peptidic alpha(v)beta3 antagonists containing indol-1-yl propionic acids.
Johnson & Johnson Pharmaceutical Research and Development
16
Nonpeptide alpha V beta 3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone.
Merck Research Laboratories
10
Docking studies on alphavbeta3 integrin ligands: pharmacophore refinement and implications for drug design.
Technische Universit£T M£Nchen
6
Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist.
Merck Research Laboratories
5
Synthesis and solution conformation of cyclo[RGDRGD]: a cyclic peptide with selectivity for the alpha V beta 3 receptor.
Texas A&M University
1
Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist.
Merck Research Laboratories
10
Non-peptide alpha v beta 3 antagonists. Part 7: 3-Substituted tetrahydro-naphthyridine derivatives.
Merck Research Laboratories
40
Biphenyls as potent vitronectin receptor antagonists. Part 2: biphenylalanine ureas.
Bayer
6
Non-peptide alpha(v)beta(3) antagonists: identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint.
Merck Research Laboratories
13
Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacements.
Merck Research Laboratories
11
Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics.
Merck Research Laboratories
31
Synthesis of highly potent and selective hetaryl ureas as integrin alpha(V)beta3-receptor antagonists.
Basf
16
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements.
Merck Research Laboratories
10
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide.
Merck Research Laboratories
15
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model.
Smithkline Beecham Pharmaceuticals
15
Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrinaVß3.
University of Milan
9
Camptothecins in tumor homing via an RGD sequence mimetic.
Sigma-Tau Industrie Farmaceutiche Riunite
3
Near-infrared fluorescent divalent RGD ligand for integrinavß3-targeted optical imaging.
Washington University
2
¹²5I-radiolabeled morpholine-containing arginine-glycine-aspartate (RGD) ligand ofavß3 integrin as a molecular imaging probe for angiogenesis.
University of Florence
24
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 1.
AstraZeneca
34
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targetinga5ß1: part 2.
AstraZeneca
10
Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics.
Universita Degli Studi Di Bologna
22
alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers.
Universite Catholique De Louvain
4
Synthesis, SAR and in vitro evaluation of new cyclic Arg-Gly-Asp pseudopentapeptides containing a s-cis peptide bond as integrin alphavbeta3 and alphavbeta5 ligands.
Department of Organic Chemistry Ugo Schiff University of Firenze Via Della Lastruccia 13
12
Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues.
University of Parma
18
Design and synthesis of novel potent and selective integrin alphanubeta3 antagonists--novel synthetic routes to isoquinolinone, benzoxazinone, and quinazolinone acetates.
Basf
8
Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
Johnson & Johnson Pharmaceutical Research and Development
14
Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.
University of Parma
13
Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands.
3-Dimensional Pharmaceuticals
37
Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents.
Genentech
6
Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.
Merck Research Laboratories
14
RGD mimetics containing a central hydantoin scaffold: alpkha(v)beta3 vs alpha(IIb)beta3 selectivity requirements.
Hoechst Marion Roussel
40
Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold.
University of Ljubljana
28
Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry.
The University of Tokyo
3
Small molecule inhibitors of hantavirus infection.
University of New Mexico School of Medicine
14
Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis.
University of Florence
9
Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation.
Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni
10
Switching Roles─Exploring Concentration-Dependent Agonistic versus Antagonistic Behavior of Integrin Ligands.
TUM University Hospital
11
Sidechain structure-activity relationships of cyclobutane-based small molecule αvβ3 antagonists.
University of Bradford
8
Multiple N-methylation by a designed approach enhances receptor selectivity.
Technische UniversitäT MüNchen
15
Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides.
Bayer Healthcare
16
Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds.
Università
20
Design and synthesis of a new class of selective integrin alpha5beta1 antagonists.
Jerini
20
Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization.
Pfizer
42
Fused-azepinones: Emerging scaffolds of medicinal importance.
National Institute of Pharmaceutical Education and Research (NIPER)
8
Halting the Spread of Herpes Simplex Virus-1: The Discovery of an Effective Dual αvβ6/αvβ8 Integrin Ligand.
University of Naples Federico II
23
Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists.
Pfizer
15
Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study of their conformational and biological behavior.
Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni
21
Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic properties.
Pfizer
25
Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.
Pfizer
10
Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists.
Università
4
Nonpeptide alpha(v)beta3 antagonists: identification of potent, chain-shortened 7-oxo RGD mimetics.
Merck Research Laboratories
4
Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.
Johnson and Johnson Pharmaceutical Research & Development
4
Sortase A-mediated cyclization of novel polycyclic RGD peptides for α
Hefei Normal University
10
1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability.
Johnson & Johnson Pharmaceutical Research & Development
3
Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of Gemcitabine.
Aristotle University of Thessaloniki
22
Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.
Johnson & Johnson Pharmaceutical Research and Development
15
Discovery of a potent and selective alpha v beta 3 integrin antagonist with strong inhibitory activity against neointima formation in rat balloon injury model.
Dainippon Pharmaceutical
44
Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
Millennium Pharmaceuticals
49
Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonists.
Pfizer
39
Solid-phase synthesis of a small library of 3-phenylthio-3-nicotinyl propionic acid derivatives acting as antagonists of the integrin alphaVbeta3.
Nerviano
7
Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis.
Merck Research Laboratories
4
Design, synthesis, and biological evaluation of novel bifunctional thyrointegrin antagonists for neuroblastoma.
Pharmaceutical Research Institute
18
Tuning the Biological Activity of RGD Peptides with Halotryptophans†.
Bielefeld University
25
Non-peptide alphavbeta3 antagonists. Part 6: design and synthesis of alphavbeta3 antagonists containing a pyridone or pyrazinone central scaffold.
Merck Research Laboratories
6
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.
Glaxosmithkline
3
Solid-phase synthesis of cyclic RGD-furanoid sugar amino acid peptides as integrin inhibitors.
Leiden University
46
Highly potent and selective alphaVbeta3-receptor antagonists: solid-phase synthesis and SAR of 1-substituted 4-amino-1H-pyrimidin-2-ones.
Basf
8
Binding model for nonpeptide antagonists of alpha(v)beta(3) integrin.
Merck Research Laboratories
10
Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists.
Institut De Recherches Servier
14
Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness.
University of California San Francisco
15
Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.
Merck
19
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
University of Bologna
25
Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel potent and selective alpha(V)beta(3) antagonists.
Knoll
8
Discovery and evaluation of piperidinyl carboxylic acid derivatives as potent alpha(4)beta(1) integrin antagonists.
Bayer
8
Novel cilengitide-based cyclic RGD peptides as αvβ
Division of Organic Chemistry Csir-National Chemical Laboratory (Ncl)
32
alpha(v)beta(3) Antagonists based on a central thiophene scaffold.
Aventis Pharma Deutschland
17
Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes.
Cor Therapeutics
46
Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists.
Technische UniversitäT MüNchen
9
2-Acylimino-3H-thiazoline derivatives: a novel template for platelet GPIIb/IIIa receptor antagonists.
Taisho Pharmaceutical
2
Dual Targeting of Norepinephrine Transporter (NET) Function and Thyrointegrin αvβ3 Receptors in the Treatment of Neuroblastoma.
Albany College of Pharmacy and Health Sciences
16
Insights into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations.
Pliant Therapeutics
15
Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists.
Celltech Chiroscience
58
Selective Targeting of Integrin αvβ8 by a Highly Active Cyclic Peptide.
Technische Universit£T M£Nchen
51
Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3).
Dupont Pharmaceuticals
30
Isoxazolines as potent antagonists of the integrin alpha(v)beta(3).
Dupont Pharmaceuticals
7
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.
Smithkline Beecham Pharmaceuticals
7
N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.
Technische UniversitäT MüNchen
5
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.
Smithkline Beecham Pharmaceuticals
18
Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics.
Smithkline Beecham Pharmaceuticals
32
Rapid synthesis of RGD mimetics with isoxazoline scaffolds on solid phase: identification of alphavbeta3 antagonists lead compounds.
Dupont Pharmaceuticals
5
Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.
Dupont Pharmaceuticals
13
Profile of a Highly Selective Quaternized Pyrrolidine Betaine α
Glaxosmithkline Medicines Research Centre
40
Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists.
Smithkline Beecham Pharmaceuticals
24
Discovery of an Orally Bioavailable Pan αv Integrin Inhibitor for Idiopathic Pulmonary Fibrosis.
Glaxosmithkline Medicines Research Centre
38
Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors.
Cor Therapeutics
36
Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.
Eli Lilly
14
Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists.
Smithkline Beecham Pharmaceuticals
14
Could Dissecting the Molecular Framework of β-Lactam Integrin Ligands Enhance Selectivity?
University of Bologna
2
Insight to the binding mode of triazole RGD-peptidomimetics to integrin-rich cancer cells by NMR and molecular modeling.
University of Milano
7
Dehydro-β-proline Containing α4β1 Integrin Antagonists: Stereochemical Recognition in Ligand-Receptor Interplay.
University of Bologna
4
In silico studies, synthesis and binding evaluation of substituted 2-pyrrolidinones as peptidomimetics of RGD tripeptide sequence.
Paris Descartes University
21
Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.
University of Bradford
35
Structure Activity Relationships of αv Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents.
University of Nottingham
50
Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.
Merck Research Laboratories
13
Natural inhibitors targeting osteoclast-mediated bone resorption.
Chinese Academy of Sciences
30
Discovery of ( S)-3-(3-(3,5-Dimethyl-1 H-pyrazol-1-yl)phenyl)-4-(( R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic α
University of Strathclyde
6
Succinimide-Based Conjugates Improve IsoDGR Cyclopeptide Affinity to α
Irccs Ospedale San Raffaele
16
Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme.
University of Naples Federico II
4
Synthesis of a Chloroalkene Dipeptide Isostere-Containing Peptidomimetic and Its Biological Application.
Tokyo Medical and Dental University
18
Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.
Merck Research Laboratories
